PVLA · Palvella Therapeutics, Inc.
$138.01
+0.75% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-22.2
Dividend yield
—
Beta
—
Avg volume
0M
Employees
0K
2D change
—
5D change
-1.00%
10D change
-9.84%
30D change
-4.35%
60D change
19.68%
MTD change
2.54%
YTD change
35.44%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PVLA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-21
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-21 | Stephens & Co. | Reiterates | Overweight | $220 |
| 2026-05-21 | Chardan Capital | Maintains | Buy | $240 |
| 2026-05-12 | Stephens & Co. | Initiates | Overweight | $0.00 → $220 |
| 2026-03-31 | Chardan Capital | Maintains | Buy | $210 → $240 |
| 2026-03-24 | HC Wainwright & Co. | Maintains | Buy | $255 → $270 |
| 2026-03-16 | Chardan Capital | Maintains | Buy | $210 |
| 2026-02-25 | Mizuho | Maintains | Outperform | $205 → $250 |
| 2026-02-25 | BTIG | Maintains | Buy | $192 → $215 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 52 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 12.3% above the 50-day MA ($127.18).
- Price vs 200-day MA: Trading 32.1% above the 200-day MA ($108.10).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.62) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($36.55) and high ($157.24).
PVLA Price Chart
Loading chart for PVLA…
Fundamentals
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.